Skip to main content

Table 3 Patient-reported improvement, headache frequency, and migraine pain intensity

From: Real-world impact of fremanezumab on migraine symptoms and resource utilization in the United States

Parameter

 

P value

Improvement, n (%)a

(n = 129)

 

 Yes

108 (84)

 

 No

21 (16)

 

Headache frequency (overall)

(n = 54)

 

 Pre-index, mean (SD)

22.24 (9.29)

 

 Post-index, mean (SD)

8.24 (7.42)

 

 Difference in days, meanb

14.00

< 0.001

 Difference %, mean

63%

 

MPI (overall)

(n = 74)

 

 Pre-index, mean (SD)

5.47 (3.19)

 

 Post-index, mean (SD)

4.51 (3.34)

 

 Difference in days, meanb

0.96

0.014

 Difference %, mean

18%

 
  1. SD standard deviation, MPI migraine pain intensity
  2. aNot reported, n = 43
  3. bNonparametric Wilcoxon signed-rank tests, with a level of significance set at P < 0.05, were used to compare means of patient-reported headache frequency and MPI before and after fremanezumab initiation